C
Changquan Calvin Sun
Researcher at University of Minnesota
Publications - 248
Citations - 10301
Changquan Calvin Sun is an academic researcher from University of Minnesota. The author has contributed to research in topics: Tableting & Cocrystal. The author has an hindex of 45, co-authored 223 publications receiving 8070 citations. Previous affiliations of Changquan Calvin Sun include Pharmacia & Pfizer.
Papers
More filters
Posted ContentDOI
On the elasticity of Copper(II)acetylacetonate crystals
TL;DR: In this paper, the authors conducted detailed experiments on crystals of 1.5 µm and found that they indeed readily undergo plastic deformation when bent on the (101) face, which contradicts Worthy et al.'s assertion that the face is highly elastic.
Journal ArticleDOI
Effect of deaeration on processability of poorly flowing powders by roller compaction.
TL;DR: In this paper , the authors examined the effect of vacuum on the processability of RC using an extremely poorly flowing powder, colloidal silica, and two grades of microcrystalline cellulose (MCC).
Journal ArticleDOI
Nanomechanical testing in drug delivery: theory, applications, and emerging trends.
TL;DR: A review of existing and emerging nanomechanical testing methods in characterizing mechanical properties of pharmaceutical solids to facilitate fast and cost-effective development of high quality drug products is presented in this paper .
Journal ArticleDOI
A Rheological Approach for Predicting Physical Stability of Amorphous Solid Dispersions.
TL;DR: In this article , a method of miscibility determination based on the overlap concentration, c*, which can be conveniently determined from the viscosity-composition diagram, is presented. But this method is not applicable to thermally stable binary drug/polymer combinations.
Journal ArticleDOI
Profound effects of gastric secretion rate variations on the precipitation of erlotinib in duodenum - an in vitro investigation.
Yiwang Guo,Changquan Calvin Sun +1 more
TL;DR: In this paper , the pH-dependent precipitation of erlotinib (ERL) during dissolution in the gastrointestinal (GI) tract by varying the rate of gastric fluid secretion (RGFS) was investigated.